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Abstract
Background: The goal of this study was to detect
modification in the expression of plasma proteins
and/or post-translational modifications of their struc-
ture in patients with end stage renal disease.
Methods: Serum samples from 19 adult patients treat-
ed by maintenance hemodialysis (MHD) were ana-
lyzed in comparison to sera from six healthy controls
using sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and two-dimensional
electrophoresis (2DE). Spots of interest were identified
by mass spectrometry analysis. In addition, the 2DE
maps were incubated with a human anti-albumin
polyclonal antibody.
Results: SDS-PAGE gels, 2DE maps and matrix-assist-
ed laser desorption/ionization time of flight analysis
indicated over-expression of low-molecular weight
proteins (LMWP) in sera from patients. Unexpectedly,
another 15 spots with estimated Mr of 12.5–29 kDa
from the 2DE maps of six patients were identified as
fragments of albumin. 2D immunoblotting of sera
from 12 other patients detected numerous albumin
fragments.
Conclusions: These results indicate that in addition to
increased expression of LMWP, a relevant amount of
albumin fragments are detectable in the serum of
patients undergoing MHD. Uremia appears to facili-
tate the fragmentation of albumin and/or the retention
of albumin fragments in blood.
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Introduction
The kidney plays a central role in the regulation of
plasma concentrations of low-molecular weight pro-
teins (LMWP) and human serum albumin (HSA). In
particular, the kidney determines the rate of plasma
metabolic clearance of LMWP. These proteins are fil-
tered from the plasma through renal glomeruli with a
high filtration coefficient. Following filtration, LMWP
are reabsorbed by proximal tubular cells through the
brush border via endocytosis and are accumulated
inside tubular cells where they are completely cata-
bolized (1, 2). Plasma clearance of many LMWP
wcystatin C, lysozyme, b2-microglobulin, a1-microglo-
bulin (AMBP), b-trace protein, chromograninx
depends upon the glomerular filtration rate (GFR)
(3–9). In patients with end-stage renal disease (ESRD),
decreased GFR leads to increases in the plasma
concentration of some LMWP (i.e., parathormone,
b2-microglobulin, and probably others not yet discov-
ered). These proteins, together with other uremic tox-
ins may cause the uremic syndrome. Hemodialysis,
the most common treatment for uremic syndrome,
cannot completely clear all accumulated uremic tox-
ins from the blood, in particular those with a molec-
ular weight )1000 Da. The persistent increase in the
serum concentrations of some uremic toxins (i.e., b2-
microglobulin) is a determinant of dementia and amy-
loidosis which may occur in maintenance hemo-
dialysis (MHD) patients. HSA has important physio-
logical functions, such as the maintenance of plasma
oncotic pressure, transport of hormones and other
biological compounds and xenobiotics, and antioxi-
dant proprieties. Recent studies demonstrated that
the urine of diabetic patients has a high prevalence of
HSA fragments (10). Recently, it has been demon-
strated that oxidative stress increases fragmentation
and carbonylation of plasma and urinary albumin,
and also determines alteration in the redox state of
HSA (11). Inflammation, common in MHD, can lead to
fragmentation of HSA through a marked increase in
serum proteases. Thus, it is possible to hypothesize
that post-translational modifications to HSA can occur
in patients with ESRD.
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The goal of this study was to evaluate the utility of
a proteomic analysis of serum from patients under-
going MHD to identify alterations in the expression of
LMWP and/or modifications to the structure of HSA.
Patients and methods
Study design
Proteomic analysis, by means of sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), two-
dimensional electrophoresis (2DE), immunoblotting and
matrix-assisted laser desorption/ionization time of flight
mass spectrometry (MALDI-TOF) analysis, was performed
using serum collected from MHD patients, and compared
with normal subjects. MHD patients were in stable clinical
condition and undergoing treatment for at least 6 months at
a University-based hemodialysis clinic. Blood samples were
collected from MHD patients prior to the start of dia-
lysis. Blood samples were also collected by healthy fasting
individuals. All samples were prepared according to Aresta
et al. (12). Briefly, they were collected in iced tubes from
patients with ESRD at the start of a dialysis session,
and before breakfast from controls. Samples from patients
and controls were centrifuged within 30 min after clotting
and the sera stored at –208C until analysis.
Patients
Nineteen adult patients (F7, M12; 32–88 years, mean 67) with
ESRD due to various renal diseases (chronic glomerulone-
phritis six patients; chronic kidney disease four patients;
ischemic renal disease four patients; renal cancer, diabetes
type 2, urinary tract malformation, interstitial nephritis, and
Alport syndrome, one patient each). All patients were in sta-
ble conditions without evidence of current inflammatory dis-
ease and treated with MHD (hemodialfiltration, bicarbonate
dialysis or acetate-free biofiltration) for more than 6 months.
Six normal subjects (F4, M2; aged 28–60 years, mean 38.4)
were used for comparison. The size of this pilot investigation
was limited by the complexity of the proteomic analysis. The
study was approved by the institutional Ethical Committee
and conducted in accordance with Helsinki declaration.
Patients gave their informed consent.
Laboratory methods
SDS-PAGE An aliquot of 0.15 mL of serum (10 mg of pro-
teins) underwent SDS-PAGE according to the procedure of
Laemmli (13) using 12% or 15% T separating polyacrylamide
gels and a Miniprotean II (Bio-Rad Laboratories, Hercules,
CA, USA). Gels underwent silver staining using aMALDI-TOF
compatible protocol, according to Yan and co-authors (14).
Two-dimensional electrophoresis 2DE was performed
according to Go¨rg and co-authors (15). Briefly, an aliquot
corresponding to 80 mg of sample was mixed with 240 mL
of rehydration buffer containing 8 M urea, 2% CHAPS, 1 mM
DTT, 0.8% IPG buffer pH 3–10, 0.8% Pharmalyte pH 3–10,
and a trace of bromophenol blue. Serum samples were load-
ed onto an 11 cm Immobiline DryStrip, pH 3–10 immobilized
pH gradient DryStrips, or on an 11 cm Immobiline DryStrip,
pH 3–5.6 immobilized pH gradient DryStrips (GE Healthcare
Bio-Sciences, Uppsala, Sweden). Isoelectric Focusing was
performed with the Multiphor II apparatus (GE Healthcare
Bio-Sciences, Uppsala, Sweden) for 45,000 Vh at 158C, then
equilibrated for 8 min in 50 mM Tris-HCl, pH 8.8, containing
30% V/V glycerol, 6 M urea, 4% SDS, 2% m/V DTT, and finally
for 12 min in 50 mM Tris-HCl, pH 6.8, containing 30% V/V
glycerol, 6 M urea, 4% SDS and 2.5% m/V iodoacetamide and
trace of bromophenol blue. Second dimension electropho-
resis was performed using 12% or 15% T, 2.6% C, separating
polyacrylamide gels (1 mm tick) according to Laemmli (13)
but without stacking gels, using a Hoefer SE 600 system (GE
Healthcare Bio-Sciences, Uppsala, Sweden). The electropho-
retic run was performed according to the manufacturer’s
instructions at 30 mA per gel at 98C for 3 h and 30 min,
leaving the voltage free to vary. Before performing 2D-elec-
trophoresis, serum samples were divided in two aliquots.
One aliquot underwent HSA depletion using a Hi Trap blue
HP (GE Healthcare Bio-Science, Uppsala, Sweden) column
following the manufacturer’s instructions. HSA depletion
was performed to increase the sensitivity for low-abundance
proteins.
Gels were scanned with an Epson Expression 1680 Pro
scanner and images were analyzed with PDQuest V 6.2.1.
(Bio-Rad Laboratories, Hercules, CA, USA).
Matrix-assisted laser desorption/ionization time of flight
mass spectrometry and database search Spots of interest
were excised from the 2DE gel and destained overnight with
a solution of 25 mM ammonium bicarbonate, 50% aceto-
nitrile. The proteins were digested in-gel with trypsin as
described by Hellman et al. (16). Protein identification was
performed using peptide mass fingerprinting with an Ettan
MALDI-TOF Pro mass spectrometer (GE Healthcare Bio-Sci-
ences, Uppsala, Sweden) as described previously (16, 17).
From each protein digest, 0.75 mL of matrix solution (satured
solution of alpha-cyano-4-hydroxycynnamic acid in 50% ace-
tonitrile and 0.5% trifluoroacetic acid) was spotted onto the
MALDI target and allowed to dry. After tryptic peptide mass
acquisition, mass fingerprinting searching was performed
using Swiss-Prot/TrEMBL and NCBInr databases with
MASCOT (Matrix Science Ltd., London, UK, http://www.
matrixscience.com). A mass tolerance of 50 ppm was used
and the number of accepted missed cleavage sites was set
to one. Alkylation of cysteine by carbamidomethylation was
assumed as a fixed modification, while oxidation of methio-
nine was considered as a possible modification. The criteria
used to accept identifications included the extent of
sequence coverage, number of matched peptides and prob-
abilistic scores. By default, the significance level was set at
5%.
Immunoblotting After 2DE, proteins on the gel were trans-
ferred electrically to a polyvinylidene difluoride membrane
(Hybond-P PVDF, Amersham Biosciences, Piscataway, NJ,
USA) using a Pharmacia LKB Nova Blot (GE Healthcare Bio-
Sciences, Uppsala, Sweden) semi-dry transfer apparatus and
using the Towbin buffer. According to Towbin’s protocol, a
constant current of 0.8 mA/cm2 gel was applied for 1 h at
room temperature, leaving the voltage free to vary. The
membrane was saturated for 1 h at room temperature with
3% skim milk in PBS. This was followed by an overnight
incubation at 48C with Polyclonal Anti-Human HSA serum
(DakoCytomation, Glostrup, Denmark) at 1:1000 dilution in
PBS under mild shaking. After three washings in 0.05%
Tween in PBS, a 1 h incubation with 1:1000 diluted goat anti-
rabbit IgG peroxidase conjugate antibody (Sigma-Aldrich,
St. Louis, Missouri, USA) was followed by four washings in
PBS. Color development was accomplished using a solution
of 5 mM 4-chloro-1-naphtol, 6% methanol and 0.025%hydro-
gen peroxide in PBS solution.
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Figure 1 Silver stained 2DE of serum proteins belonging to 2 healthy controls (n1, n2) and 6 patients affected by end-stage
renal disease (ESRD).
Gels were run first using a 3–10 pH gradient followed by SDS-PAGE. The spots are identified with numbers and letters
corresponding to numbers and letters in Table 1.
Results
SDS-PAGE of the 19 uremic sera indicated an increase
in LMWP. In particular, bands corresponding to a
molecular weight (MW) between 5 and 26 kDa were
observed (data not shown).
2DE of 12 patients, performed without HSA deple-
tion in the range 3–10 pH, demonstrated an increase
in the expression of LMWP between 14 and 24 kDa
when compared with control samples, where these
spots are absent or present only in low amounts (Fig-
ure 1). 2DE of sera from two patients with ESRD, per-
formed in the range 3–10 pI following depletion of
HSA, demonstrated over-expression of different spots
in the range of 6.5–29 kDa (Figure 2). Similarly, 2DE
of sera from two other patients, performed without
HSA depletion in the range 3–5.6 pH, demonstrated
over-expression of different spots in the range
between 17 and 32 kDa (Figure 3). MALDI-TOF anal-
ysis identified these spots (c–h, Table 1 and Figure 3)
as fragments of immunoglobulins, a1-microglobulin
precursor, leukotriene A4 hydrolase variant, chain L
crystal structure of Fab D3h44, retinol binding protein
and transthyretin. Unexpectedly, 15 spots, analyzed
by MALDI-TOF, and isolated from the gels performed
in the range of 3–10 pH with estimated MW rang-
ing from 12.5 to 29 kDa (1–15, Table 1, Figures 1 and
2) were identified as fragments of HSA. In a
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Figure 2 Silver stained 2DE of serum proteins belonging to a healthy control (n2) and two patients on maintenance
hemodialysis.
Prior to electrophoresis, serum samples were depleted of albumin by use of Hi Trap blue HP (GE Healthcare). Gels were run
first using a 3–10 pH gradient followed by SDS-PAGE. Spots are identified with numbers corresponding to numbers in Table
1 and Figure 4.
Figure 3 Silver-stained 2DE of serum proteins from a healthy control (n1) and a patient on maintenance hemodialysis.
Gels were run first using a 3–5.6 pH gradient followed by SDS-PAGE. The spots are identified with letters corresponding to
those in Table 1.
young patient affected by the Prune Belly syndrome,
the fragments were from different variant forms of
HSA (the corresponding spots in Table 1 are indicated
by an asterisk). The great majority of fragments of
HSA were determined to be from the carboxy termi-
nal part of the molecule, starting from amino acids
380–400 or 500–509 (Figure 4). In some cases, frag-
ments originating from the N-terminal part of themol-
ecule of HSA were identified. The terminal amino acid
of each fragment was Arginine or Lysine, indicating
that the molecule was cleaved by a trypsin-like
protease.
Immunoblotting performed using 12 sera from
patients with uremia demonstrated the presence of
several immunoreactive fragments of HSA ranging
from 14 to 22 kDa. This was much greater than that
seen in normal sera (data not shown).
Discussion
This study, performed in a small group of stable
patients undergoing MHD, indicates that it is possible
to identify over-expression of many LMWP in serum
using proteomic techniques. In addition, proteomic
analysis allowed for the detection of HSA fragments
in serum of MHD patients.
The literature suggests that proteomics has the
potential to detect new markers of renal disease and
to unravel the pathophysiology of uremia (18). In par-
ticular, using gel electrophoresis in combination with
mass spectrometry, 292 proteins have been identified
in hemodialysis fluid. More than 70% of these pro-
teins had not previously been identified in serum and
more than 50% were LMWP, smaller than 40 kDa (19).
Thus, the increase in LMWP appears particularly rel-
evant in ESRD. In our study, the removal of HSA and
other abundant serum proteins resulted in a sample
more concentrated in low abundance proteins that
allowed the identification of LMWP. Furthermore,
precise separation of the different spots on 2DE gels
allowed us to identify either LMWP or HSA fragments
which were obtained in the range of pI that we
investigated.
The detection of HSA fragments in serum of
patients with ESRD is the major novel finding in the
present study. HSA fragments have been found pre-
viously in urine samples. In particular, the urine of
diabetic patients has a high prevalence of immunoun-
reactive HSA, whose structure consists of polypeptide
chains held together by non-covalent and disulfide
bonds (10). In the blood of type 1 diabetic patients
with albuminuria, fragments of radio-labeled HSA
have been found possibly deriving from HSA reab-
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Table 1 Serum proteins identified by mass spectrometry.
Figure Spot MW pI Matched Sequence Mass, pI Accession No. ID name
ref. name observed, observed peptides coverage, % kDa
kDa
1 1 14.5 4.62 6 10 71317 5.92 P02768 HSA precursor
1 2 16.6 4.89 7 9 71317 5.92 P02768 HSA precursor
1 3 17.8 5.77 6 10 71317 5.92 P02768 HSA precursor
1 4 14.4 5.93 6 9 71317 5.92 P02768 HSA precursor
1 5 16.1 6.68 5 9 71317 5.92 P02768 HSA precursor
1 6 15.5 6.82 7 11 71317 5.92 P02768 HSA precursor
1 7 15.2 7.37 4 8 71317 5.92 P02768 HSA precursor
1 8 25.6 5.95 7 8 71317 5.92 P02768 HSA precursor
2 9 29.0 7.00 9 18 71317 5.92 P02768 HSA precursor
2 10a 25.0 7.02 8 16 71317 5.92 P02768 HSA, Variant maku
2 11a 28.9 7.19 9 18 71317 5.92 P02768 HSA, Variant coari I/
Porto alegre
2 12a 24.9 7.22 8 16 71317 5.92 P02768 HSA, Variant coari I/
Porto alegre
2 13a 14.7 7.20 6 11 71317 5.92 P02768 HSA, Variant
church bay
2 14a 13.8 7.38 7 11 71317 5.92 P02768 HSA, Variant coari I/
Porto alegre
2 15 12.5 7.28 8 16 71317 5.92 P02768 HSA precursor
1 a 21.4 6.21 3 14 45861 6.13 P00738 Haptoglobin precursor
1 b 18.1 6.05 7 72 15991 5.52 P02766 Transthyretin precursor
3 c 17.0 4.72 4 48 15991 5.52 P02766 Transthyretin precursor
3 d 22.4 4.72 8 56 23337 5.76 P02753 Retinol-binding
protein precursor
3 e 24.8 5.04 4 31 23770 6.99 giN18655503 Chain L, Crystal
structure of Fab D3h44
3 f 27.2 5.09 4 28 24626 6.53 giN62089060 Leukotriene A4
hydrolase variant
3 g 32.4 4.36 5 23 39986 5.95 P02760 AMBP protein
precursor
3 h 32.3 4.13 4 18 39986 5.95 P02760 AMBP protein
precursor
HSA, human serum albumin; AMBP, a1-microglobulin; aindicates the variant forms of albumin; MW, molecular weight; pI,
isoelectric point.
sorbed by proximal tubular cells before undergoing
degradation (20). In addition, the presence of HSA
fragments in urine of patients with idiopathic nephri-
tic syndrome has been demonstrated (21). Low con-
centrations of HSA fragments were also found in the
plasma of these same patients. Data from the litera-
ture indicate that fragmentation of HSA occurs in the
urine, and possibly in the serum of diabetics and
patients with proteinuria. Until now, no data were
available regarding HSA fragments in the serum of
MHD patients. Inflammation and oxidative stress are
commonly present in patients undergoing MHD. In
children affected by primary nephritic syndrome,
structural analysis of plasma and urinary proteins has
recently shown increased proteolysis of albumin,
together with increased oxidative stress (22). We
hypothesize that in uremic patients, oxidative stress
(11) and possibly increased susceptibility to the action
of some proteases induced by inflammation, may
cause HSA fragmentation that we observed in our
patients. This might be due to trypsin-like proteases.
Analysis of the albumin fragments does not allow one
to differentiate the cleavage products from those pro-
duced by trypsin. For HSA variants that we observed
in one patient associated with greater HSA fragmen-
tation, it is probable that the substitution of one ami-
no acid (in particular Lys for Glu or Glu for Lys), which
characterizes all the variations which we observed,
determines alterations in charge, dimension and ter-
tiary structure of HSA. These alterations may affect its
susceptibility to oxidative stress and the action of
proteases. Whatever the mechanism leading to the
production of HSA fragments, it is expected that in
subjects with normal renal function, HSA fragments
circulating in the plasma are cleared from the plasma
via glomerular filtration due to their low MW. We also
hypothesize that since the GFR in many patients
undergoing MHD is essentially zero, HSA fragments
produced by the action of serum protease are
retained in the plasma. These fragments accumulate
and affect HSA binding abilities and antioxidant prop-
erties. However, the clinical relevance of fragmenta-
tion of HSA in serum of uremic patients is unknown.
Also, the nature of fragmentation of albumin in sera
from patients affected by different types of renal dis-
ease is unknown. This topic will be explored in further
studies.
Conclusions
The serum proteome of patients with MHD is char-
acterized by over-expression of proteins and protein
fragments with a MW -30 kDa, identified as low-
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Figure 4 Schematic representation of serum albumin peptide composition as assigned by mass spectrometry to spots that
were recovered from 2D gels.
The spot numbers correspond to numbers in Table 1, Figures 1 and 2. HSA, human serum albumin.
molecular weight proteins, and as fragments of
albumin.
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